GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives

Borghini, Raffaele; Caronna, Roberto; Donato, Giuseppe; Picarelli, Antonio

doi:10.1016/j.dld.2020.03.019

Cited by 5 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One case of long-term TED use (54 mo) was reported in a patient with multidrug-resistant CD, and beneficial effects on nutritional status, a significant anti-inflammatory effect and reduction in CD clinical activity were observed[ 91 ]. A recent real-life cohort of 52 patients successfully treated with TED found that 16 had CD[ 74 ].…”

Section: Glp-2 Analogues In Crohn’s Diseasementioning

confidence: 99%

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

Pizzoferrato¹,

Puca²,

Ennas³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

Short bowel syndrome (SBS) with intestinal failure (IF) is a rare but severe complication of Crohn’s disease (CD), which is the most frequent benign condition that leads to SBS after repeated surgical resections, even in the era of biologics and small molecules. Glucagon-like peptide-2 analogues have been deeply studied recently for the treatment of SBS-IF. These drugs have a significant intestinotrophic effect and the potential to reduce the chronic dependence of SBS-IF patients on parenteral support or nutrition. Teduglutide has been approved for the treatment of SBS-IF, and apraglutide is currently in clinical development. The use of these drugs was examined with a focus on their use in CD patients.

show abstract

Section: Glp-2 Analogues In Crohn’s Diseasementioning

confidence: 99%

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

Pizzoferrato¹,

Puca²,

Ennas³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Finally, GLP-2 analog teduglutide has been successfully introduced in clinical practice as a new treatment for parenteral nutrition-dependent short bowel syndrome (207). It can effectively increase the residual intestinal absorption capacity through the induction of intestinal mucosa hypertrophy and hyperplasia, the increase of intestinal perfusion and the reduction of intestinal motility and gastric acid secretion, achieving a reduction of parenteral nutrition (208,209).…”

Section: Bioactive Pharmaceutical Molecules and Signaling Peptide-based Therapeutic Strategiesmentioning

confidence: 99%

Present and Future Therapeutic Approaches to Barrier Dysfunction

et al. 2021

View full text Add to dashboard Cite

There is converging and increasing evidence, but also uncertainty, for the role of abnormal intestinal epithelial barrier function in the origin and development of a growing number of human gastrointestinal and extraintestinal inflammatory disorders, and their related complaints. Despite a vast literature addressing factors and mechanisms underlying changes in intestinal permeability in humans, and its connection to the appearance and severity of clinical symptoms, the ultimate link remains to be established in many cases. Accordingly, there are no directives or clinical guidelines related to the therapeutic management of intestinal permeability disorders that allow health professionals involved in the management of these patients to carry out a consensus treatment based on clinical evidence. Instead, there are multiple pseudoscientific approaches and commercial propaganda scattered on the internet that confuse those affected and health professionals and that often lack scientific rigor. Therefore, in this review we aim to shed light on the different therapeutic options, which include, among others, dietary management, nutraceuticals and medical devices, microbiota and drugs, and epigenetic and exosomes-manipulation, through an objective evaluation of the scientific publications in this field. Advances in the knowledge and management of intestinal permeability will sure enable better options of dealing with this group of common disorders to enhance quality of life of those affected.

show abstract

“…In 2019, two CD patients who achieved control of intestinal inflammation and reduction of parenteral support while receiving the combination of teduglutide and biologics have been reported[ 49 ]. Notably, a CD patient treated only with teduglutide, previously unresponsive to multiple biological therapies, whose CD activity improved in parallel with nutritional status, has also been described[ 50 ], suggesting a link between teduglutide administration and clinically relevant anti-inflammatory effects[ 51 ].…”

Section: Short Bowelmentioning

confidence: 99%

Orphan patients with inflammatory bowel disease - when we treat beyond evidence

Privitera¹,

Pugliese²,

Lopetuso³

et al. 2021

WJG

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic condition that requires continuous medical treatment. To date, the medical management of patients with moderately-to-severely active IBD who develop dependence or resistance to corticosteroids is based on immunomodulator drugs. Such therapies are licenced after passing through three phases of randomized controlled trials (RCTs), and are subsequently adopted in clinical practice. However, the real-life population of IBD patients who require these therapies can significantly differ from those included in RCTs. As a matter of fact, there is a number of exclusion criteria – nearly ubiquitous in all RCTs – that prevent the enrolment of specific patients: Chronic refractory pouchitis or isolated proctitis in ulcerative colitis, short-bowel syndrome and stomas in Crohn’s disease, ileorectal anastomosis in both ulcerative colitis and Crohn’s disease, and elderly age are some representative examples. In this frontier article, we aim to give an overview of current literature on this topic, in order to address the main knowledge gaps that need to be filled in the upcoming years.

show abstract

GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives

Cited by 5 publications

References 7 publications

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

Present and Future Therapeutic Approaches to Barrier Dysfunction

Orphan patients with inflammatory bowel disease - when we treat beyond evidence

Contact Info

Product

Resources

About